Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1422, 2004-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Gemcitabine + cisplatin for NSCLC: genotype predicts survival
Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. :
Access to resources
Recommend
Bevacizumab combination improves survival in advanced NSCLC
Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. :
Cisplatin + pemetrexed as first-line therapy for advanced NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. :
Adjuvant temozolomide improves long-term survival in glioblastoma
Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. :
Adjuvant androgen suppression improves survival in prostate cancer
Inpharma, Vol. 1, Iss. 1452, 2004-01 ,pp. :